Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis
Eoin D. O’Sullivan, … , Hassan Dihazi, David A. Ferenbach
Eoin D. O’Sullivan, … , Hassan Dihazi, David A. Ferenbach
Published November 22, 2022
Citation Information: JCI Insight. 2022;7(22):e154124. https://doi.org/10.1172/jci.insight.154124.
View: Text | PDF
Research Article Cell biology Nephrology

Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis

  • Text
  • PDF
Abstract

Progressive fibrosis and maladaptive organ repair result in significant morbidity and millions of premature deaths annually. Senescent cells accumulate with aging and after injury and are implicated in organ fibrosis, but the mechanisms by which senescence influences repair are poorly understood. Using 2 murine models of injury and repair, we show that obstructive injury generated senescent epithelia, which persisted after resolution of the original injury, promoted ongoing fibrosis, and impeded adaptive repair. Depletion of senescent cells with ABT-263 reduced fibrosis in reversed ureteric obstruction and after renal ischemia/reperfusion injury. We validated these findings in humans, showing that senescence and fibrosis persisted after relieved renal obstruction. We next characterized senescent epithelia in murine renal injury using single-cell RNA-Seq. We extended our classification to human kidney and liver disease and identified conserved profibrotic proteins, which we validated in vitro and in human disease. We demonstrated that increased levels of protein disulfide isomerase family A member 3 (PDIA3) augmented TGF-β–mediated fibroblast activation. Inhibition of PDIA3 in vivo significantly reduced kidney fibrosis during ongoing renal injury and as such represented a new potential therapeutic pathway. Analysis of the signaling pathways of senescent epithelia connected senescence to organ fibrosis, permitting rational design of antifibrotic therapies.

Authors

Eoin D. O’Sullivan, Katie J. Mylonas, Rachel Bell, Cyril Carvalho, David P. Baird, Carolynn Cairns, Kevin M. Gallagher, Ross Campbell, Marie Docherty, Alexander Laird, Neil C. Henderson, Tamir Chandra, Kristina Kirschner, Bryan Conway, Gry H. Dihazi, Michael Zeisberg, Jeremy Hughes, Laura Denby, Hassan Dihazi, David A. Ferenbach

×

Figure 10

Increased expression of PDIA3 enhances TGF-β1–driven fibroblast proliferation in vitro.

Options: View larger image (or click on image) Download as PowerPoint
Increased expression of PDIA3 enhances TGF-β1–driven fibroblast prolifer...
Full figure legend with more statistical data available in Supplemental Data 1. (A) Increased levels of cell cycle proteins cyclin D1 and PCNA in renal fibroblasts in response to TGFB1 administration. P values generated by t test. (B) MTT assay readout normalized to control group demonstrating that dual treatment with pPDIA3 and TGF-β1 results in additional proliferation compared with single TGF-β1. One-way ANOVA with Bonferroni’s correction. (C) Trypan blue assay readout normalized to control group demonstrating treatment with PDIA3 and/or TGF-β1 results in additional proliferation compared with control. One-way ANOVA with Bonferroni’s correction. (D) Trypan blue assay readout normalized to control group demonstrating treatment with Loc14 reduces cell viability. One-way ANOVA with Bonferroni’s correction. (E) Coadministration of PDIA3, TGFB1, and Loc14 to human renal fibroblasts does not alter TGFBRI synthesis. Comparisons tested using 1-way ANOVA with Bonferroni’s correction. No comparisons were statistically significant at P adj < 0.05. (F) Coadministration of pPDIA3 to TGFB1-treated fibroblasts increases p-SMAD2 synthesis. Comparisons tested using 1-way ANOVA with Bonferroni’s correction. (G) Coadministration of siRNA to TGFB1-treated fibroblasts reduces p-SMAD2 synthesis. Comparisons tested using 1-way ANOVA with Bonferroni’s correction. (H) Coadministration of PDIA3 and TGFB1 to human renal fibroblasts increases SARA and p-SMAD2 synthesis. Dual treatment with PDIA3 and TGFB1 results in a greater increase compared with either alone. This effect was abolished by Loc14 administration. Comparisons tested using 1-way ANOVA with Bonferroni’s correction. (I) Time course experiment showing increased SARA protein over time following PDIA3 administration, first detectable at 6 hours after administration. One-way ANOVA with Bonferroni’s correction. (J) siRNA to SARA results in reduced levels of p-SMAD2, such that in the presence of siRNA to SARA, TGF-β1 no longer induces p-SMAD2 production in fibroblasts. One-way ANOVA with Bonferroni’s correction. *P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts